PharmX Technologies (ASX:PHX) Common Stock: A$94.01 Mil (As of Dec. 2025)


ASX:PHX PharmX Technologies Ltd ASX:PHX
40 GF Score
Price A$0.12
GF Value A$0.07
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is PharmX Technologies Common Stock?

PharmX Technologies ASX:PHX 40 Common Stock is A$94.01 Mil as of Dec. 2025. GuruFocus rates ASX:PHX with a GF Score™ of 40/100 and a GF Value™ of A$0.07 (Significantly Overvalued). The stock has 3 warning signs investors should review.

PharmX Technologies's quarterly common stock stayed the same from Dec. 2024 (A$93.97 Mil) to Jun. 2025 (A$93.97 Mil) but then increased from Jun. 2025 (A$93.97 Mil) to Dec. 2025 (A$94.01 Mil).

PharmX Technologies's annual common stock declined from Jun. 2023 (A$98.41 Mil) to Jun. 2024 (A$93.97 Mil) but then stayed the same from Jun. 2024 (A$93.97 Mil) to Jun. 2025 (A$93.97 Mil).

PharmX Technologies Common Stock Historical Data

* Premium members only.

The historical data trend for PharmX Technologies's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmX Technologies Common Stock Chart

PharmX Technologies Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 98.37 98.37 98.41 93.97 93.97

PharmX Technologies Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 93.97 93.97 93.97 93.97 94.01
ASX:PHX
40GF Score
PharmX Technologies Ltd ASX:PHX
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmX Technologies Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of A$94.01 Mil mean?
PharmX Technologies (ASX:PHX) has a Common Stock of A$94.01 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on PharmX Technologies and its competitors.
Is PharmX Technologies' Common Stock too high?
PharmX Technologies' current Common Stock is A$94.01 Mil. Overall, PharmX Technologies has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PharmX Technologies' Common Stock compare to VEEV and BTSG?
PharmX Technologies' Common Stock of A$94.01 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Healthcare Providers & Services company?
A good Common Stock depends on the Healthcare Providers & Services industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on PharmX Technologies and its competitors. PharmX Technologies's current Common Stock is A$94.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmX Technologies stock overvalued right now?
Based on GuruFocus' analysis, PharmX Technologies (ASX:PHX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.07, compared to a current price of A$0.12 — trading 71.4% above its estimated fair value. The current Common Stock is A$94.01 Mil. PharmX Technologies' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For PharmX Technologies (ASX:PHX), the current Common Stock is A$94.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PharmX Technologies (ASX:PHX) Overvalued in 2026?

Based on GuruFocus' analysis, PharmX Technologies stock appears to be overvalued. The current stock price of A$0.12 is trading 71.4% above its estimated GF Value™ of A$0.07. GuruFocus considers PharmX Technologies to be Significantly Overvalued.

Key valuation signals for ASX:PHX:

  • Common Stock: A$94.01 Mil
  • GF Value™: A$0.07 vs. price of A$0.12 (71.4% above fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the ASX:PHX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PharmX Technologies Business Description

Address 17 Castlereagh Street, Suite 11.02, Level 11, Sydney, NSW, AUS, 2000
PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.
40GF Score

Get the complete analysis for ASX:PHX

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.12
Price
A$0.07
GF Value